Back
Compare AU
Compare MQYM vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are MQYM and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
MQYM | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 4 | 72 |
Median incremental investment | $7,080.25 | $745.07 |
Median investment frequency | Monthly | Monthly |
Median total investment | $9,104.30 | $2,070.00 |
Average age group | > 35 | 26 - 35 |
Key Summary
MQYM | DRUG | |
|---|---|---|
Strategy | MQYM.AX was created on 2025-02-14 by Macquarie. The fund's investment portfolio concentrates primarily on high yield fixed income. The Fund aims to outperform the Bloomberg AusBond Bank Bill Index over the medium term (before fees) by investing in a diversified portfolio of fixed income securities, which are generally expected to be higher yielding than traditional fixed income investments. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Macquarie Global Yield Maximiser Active ETF (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) HKD - HONG KONG DOLLAR (0 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.59 % | 0.57 % |
Key Summary
MQYM | DRUG | |
|---|---|---|
Issuer | Macquarie | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.59 % | 0.57 % |
Price | $50.30 | $8.93 |
Size | N/A | $185.929 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 3.25 % | 1.81 % |
Market | ASX | ASX |
First listed date | 18/02/2025 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
MQYM | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 4 | 72 |
Median incremental investment | $7,080.25 | $745.07 |
Median investment frequency | Monthly | Monthly |
Median total investment | $9,104.30 | $2,070.00 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
MQYM | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
MQYM | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |